article thumbnail

Progress Toward a New GAD Treatment Paradigm

Fierce BioTech

Robert Barrow, Chief Executive Officer of MindMed | Generalized anxiety disorder afflicts millions however, the latest treatment was approved in 2007. Now MindMed is advancing a new treatment paradigm.

article thumbnail

Therapeutic peptide developed for triple-negative breast cancer

Drug Target Review

These findings offer a novel strategy for developing targeted treatments for triple-negative breast cancer, which currently has no approved options. The team also observed that the drug prevented in vitro cancer stem cells from self-renewing, which is a characteristic of aggressive cancer cells that supports treatment resistance.

Treatment 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Investigating antipsychotics in a Parkinson’s disease psychosis model

Drug Target Review

Treatment with mesdopetam counteracted both these features of the psychosis model, ie, restored normal levels of synchronisation and reduced HFOs. In rodents, non-human primates, as well as humans, long-term treatment with levodopa has been associated with an increase in dopamine D3 receptor expression.

Disease 105
article thumbnail

The role of STRIs in cancer

Drug Target Review

In cancer, the eIF4F complex becomes dysregulated, leading to the excessive production of these proteins, which contribute to tumour formation and resistance to treatment. STRIs represent a fundamentally different approach to cancer therapy compared to traditional treatments like chemotherapy, radiation therapy, and targeted therapies.

article thumbnail

CAR-NK cells: promising for cancer therapy

Drug Target Review

Only three of the CAR-NK studies were for the treatment of solid tumours. By themselves, the NK cells showed limited efficacy, but anti-tumour efficacy was observed with co-treatment regimens (eg, monoclonal antibodies, haematopoietic stem cell transplants, whole body irradiation) and multiple dosing (tolerated well by patients).

Therapies 118
article thumbnail

Seladelpar

New Drug Approvals

5 On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis, 6 which is a condition associated with aberrant bile acid metabolism. 2007 Jul 15;17(14):3855-9. 2007 Jul 15;17(14):3855-9. Epub 2007 May 10. 1] It is used as the lysine dihydrate salt. [1]

FDA 62
article thumbnail

Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression

The Pharma Data

Rapid and substantialimprovement in depressive symptoms achieved by 44% of patients at 2 weeks, 67% at 6 weeks (MADRS response), and sustained with long-term treatment. points at Week 6 (primary timepoint), with AXS-05 treatment. points at Week 6 (primary timepoint), with AXS-05 treatment. NEW YORK, Dec.